Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Introduction</h3><p>Traditional cancer therapy has many disadvantages such as low selectivity and high toxicity of chemotherapy, as well as insufficient efficacy of targeted therapy. To enhance the cytotoxic effect and targeting ability, while reducing the toxicity of antitumor drugs, an antibody drug conjugate (ADC) was developed to deliver small molecular cytotoxic payloads directly to tumor cells by binding to specific antibodies via linkers.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Method</h3><p>By reviewing published literature and the current progress of ADCs, we aimed to summarize the basic characteristics, clinical progress, and challenges of ADCs to provide a reference for clinical practice and further research.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>ADC is a conjugate composed of three fundamental components, including monoclonal antibodies, cytotoxic payloads, and stable linkers. The mechanisms of ADC including the classical internalization pathway, antitumor activity of antibodies, bystander effect, and non-internalizing mechanism. With the development of new drugs and advances in technology, various ADCs have achieved clinical efficacy. To date, nine ADCs have received US Food and Drug Administration (FDA) approval in the field of hematologic tumors and solid tumors, which have become routine clinical treatments.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>ADC has changed traditional treatment patterns for cancer patients, which enable the same treatment for pancreatic cancer patients and promote individualized precision treatment. Further exploration of indications could focus on early-stage cancer patients and combined therapy settings. Besides, the mechanisms of drug resistance, manufacturing techniques, optimized treatment regimens, and appropriate patient selection remain the major topics.</p></section>

Overcoming limitations and advancing the therapeutic potential of antibody-oligonucleotide conjugates (AOCs): Current status and future perspectives

Targeting cancer with antibody-drug conjugates: Promises and challenges

Unlocking the potential of antibody–drug conjugates for cancer therapy

Spotlight on Ideal Target Antigens and Resistance in Antibody-Drug Conjugates: Strategies for Competitive Advancement

Antibody-Drug Conjugates: A promising breakthrough in cancer therapy

A comprehensive review of key factors affecting the efficacy of antibody drug conjugate

Antibody–drug conjugates come of age in oncology

Development of antibody-drug conjugates in cancer: Overview and prospects

The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively

Recent Technological and Intellectual Property Trends in Antibody–Drug Conjugate Research

Exploring the next generation of antibody–drug conjugates

Drug conjugate-based anticancer therapy - Current status and perspectives

The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development

Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions

Antibody drug conjugates: Design implications for clinicians

Precision Targeting in Oncology: the Future of Conjugated Drugs

The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors

Advances and Limitations of Antibody Drug Conjugates for Cancer

Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies

Antibody-drug Conjugates and Their Application in the Treatment of Hematological Malignancies

Antibody-drug Conjugates: Design and Clinical Progress